Sydney Lupkin
Stories
-
The FDA will lift warnings on hormone therapy for menopause
Hormone therapy drugs have carried box warning labels for years. The Food and Drug Administration is removing them, saying the risks were overstated.
-
White House strikes new deals to lower prices on obesity drugs for some
The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for type 2 diabetes and obesity drugs --- but not everyone will qualify.
-
White House strikes deals for lower prices on obesity drugs
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations.
-
Searching 'weight' can bring up Ozempic in results. It's a drug advertising loophole
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle room when companies pay to sponsor online search results.
-
AstraZeneca makes deal with White House to lower drug prices
The U.K.-based drugmaker became the second to strike a deal with the Trump administration as part of the president's push to rein in U.S. drug prices.
-
Patients turn to 'gray market' for cheaper obesity drugs, but it's risky
Patients who want a deeper discount on obesity meds than compounding pharmacies can offer are turning to the gray market, where they buy the raw active ingredient from China and prepare it themselves.
-
President Trump announces deal with Pfizer to sell its drugs on federal website
President Trump on Tuesday announced a deal with Pfizer to sell its drugs directly to consumers at discounted prices. They'll be available through a website operated by the federal government.
-
President announces TrumpRx website for drugs, and pricing deal with Pfizer
The Trump administration says it is making deals with drug companies to lower prices U.S. consumers pay for medicines. But key details are missing on how the initiative would work.
-
Trump deadline for drugmakers to lower prices comes due
The Trump administration sent letters this summer to 17 makers of name-brand drugs pushing them to lower prices to align them with what other countries pay. The companies had 60 days to "step up."
-
Lawsuits against Tylenol's maker get a boost after Trump's comments
A law firm appealing a stalled case against Tylenol's maker, Kenvue, says people are calling to join the suit, alleging the painkiller caused autism in children whose mothers took it during pregnancy.
